Budget Impact of Lasmiditan for the Acute Treatment of Migraine in the United States

被引：0
|
作者：
Milev, S. [1 ]
Pohl, G. M. [2 ]
Sun, A. [1 ]
Mason, O. [2 ]
Njuguna, N. [2 ]
Loo, L. [2 ]
机构：
[1] Evidera Inc, San Francisco, CA USA
[2] Eli Lilly, Indianapolis, IN USA
来源：
HEADACHE | 2020年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [21] BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES
    Foster, S. A.
    Milev, S.
    Hoog, M.
    Mason, O.
    Sardesai, A.
    Hasan, A.
    Marrone, C.
    VALUE IN HEALTH, 2019, 22 : S277 - S277
  • [22] The current state of acute treatment for migraine in adults in the United States
    Cooper, Wade
    Doty, Erin Gautier
    Hochstetler, Helen
    Hake, Ann
    Martin, Vincent
    POSTGRADUATE MEDICINE, 2020, 132 (07) : 581 - 589
  • [23] Profiling lasmiditan as a treatment option for migraine
    Curto, Martina
    Cipolla, Fabiola
    Cisale, Giusy Ylenia
    Capi, Matilde
    Spuntarelli, Valerio
    Guglielmetti, Martina
    Martelletti, Paolo
    Lionetto, Luana
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (02) : 147 - 153
  • [24] Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
    Knievel, Kerry
    Buchanan, Andrew S.
    Lombard, Louise
    Baygani, Simin
    Raskin, Joel
    Krege, John H.
    Loo, Li Shen
    Komori, Mika
    Tobin, Joshua
    CEPHALALGIA, 2020, 40 (01) : 19 - 27
  • [25] Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
    Kuca, Bernice
    Silberstein, Stephen D.
    Wietecha, Linda
    Berg, Paul H.
    Dozier, Gregory
    Lipton, Richard B.
    Adams, Michael
    Alftine, Christopher
    Allaw, Mohammed
    Allen, Lawrence
    Ampajwala, Madhavi
    Bakhtari, Ladan
    Bhasker, Kala
    Bird, David
    Bolshoun, David
    Brown, Judith
    Brownstone, Paul
    Bruce, Tami
    Burke, Dina
    Chuang, Rita
    Conrady, Rickie
    Davis, Bethany
    Davis, Cedrice
    Dawson, Mark
    Desantis, Donna
    Dushkin, Holly
    Ellison, William
    Ervin, John
    Essink, Beal
    Fakhouri, Ibrahim
    Fiel, Thomas
    Fitzgibbons, William
    Francyk, David
    Geisberg, Harry
    Geohas, Jeff
    Giep, Son
    Glover, Richard
    Godbole, Narendra
    Grainger, William
    Griffin, Carl
    Halpern, Steven
    Han, Michael
    Hiotis, Louis
    Huffman, Cynthia
    Hummel, Matthew
    Hurley, Donald
    Inzerello, Anthony
    Jagielo, Ted
    Jennings, William
    Kaiser, Scott
    NEUROLOGY, 2018, 91 (24) : E2222 - E2232
  • [26] Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
    Oswald, Jessica C.
    Schuster, Nathaniel M.
    JOURNAL OF PAIN RESEARCH, 2018, 11 : 2221 - 2227
  • [27] Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review
    Ferrari, Anna
    Rustichelli, Cecilia
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 654 - 670
  • [28] BUDGET IMPACT ANALYSIS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES
    Nesheim, J.
    Chen, J., V
    Gahn, J. C.
    Mudd, P.
    VALUE IN HEALTH, 2021, 24 : S234 - S235
  • [29] THE BUDGET IMPACT OF ZANUBRUTINIB FOR THE TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Campbell, D.
    Zimmerman, T.
    Migliaccio-Walle, K.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (07) : S430 - S431
  • [30] Response to lasmiditan for acute treatment of migraine based on prior response to triptan therapy
    Knievel, Kerry
    Lombard, Louise
    Buchanan, Andrew
    Baygani, Simin
    Raskin, Joel
    Tobin, Joshua
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
12345